During the past decade, Gemeinschaftspraxis für Hämatologie und Onkologie conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gemeinschaftspraxis für Hämatologie und Onkologie" #1 sponsor was "iOMEDICO AG" with 3 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "University Hospital Tuebingen" with 2 trials sponsored, "Celgene" with 1 trials sponsored and "Onco Medical Consult GmbH" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gemeinschaftspraxis für Hämatologie und Onkologie" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Novartis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Gemeinschaftspraxis für Hämatologie und Onkologie" are "Metastatic Breast Cancer" (2 trials), "Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC" (1 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials), "Breast Cancer" (1 trials) and "Extensive-stage Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Gemeinschaftspraxis für Hämatologie und Onkologie" in a lesser frequency.

Most popular intervention types in "Gemeinschaftspraxis für Hämatologie und Onkologie" are "Drug" (3 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab" (1 trials), "Lenalidomide" (1 trials), "Ribociclib and aromatase inhibitor or fulvestrant" (1 trials) and "eHealth system support for symptom management via CANKADO" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gemeinschaftspraxis für Hämatologie und Onkologie" are 7 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Gemeinschaftspraxis für Hämatologie und Onkologie". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Gemeinschaftspraxis für Hämatologie und Onkologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Gemeinschaftspraxis für Hämatologie und Onkologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".